Growth conditions and isolation of genomic DNA: For each experiment, plasmids were freshly transformed in E. coli DH10B by electroporation. The cells were plated under antibiotic selection pressure and arabinose induction. Individual colonies were picked and the inoculated in LB media in the presence of antibiotics. The cultures were incubated at 37 o C for 18 to 22 hrs. The cells were harvested by centrifugation. The genomic DNA was isolated by Purelink genomic DNA isolation minikit using the manufacturer's protocol. Minimal media growth consisted of M9 minimal salts were used along with glucose or glycerol as the carbon source, MgSO 4 , CaCl 2 and defined antibiotics (see Table S1 for antibiotic resistance and origin of replication for the plasmids used in this study).
o C for 18 to 22 hrs. The cells were harvested by centrifugation. The genomic DNA was isolated by Purelink genomic DNA isolation minikit using the manufacturer's protocol. Minimal media growth consisted of M9 minimal salts were used along with glucose or glycerol as the carbon source, MgSO 4 , CaCl 2 and defined antibiotics (see Table S1 for antibiotic resistance and origin of replication for the plasmids used in this study).
Digestion of the genomic DNA template to individual nucleosides: Genomic DNA template (25ng/µL) was incubated with phosphodiesterase I (MP biomedical), calf intestinal phosphatase (NEB) and benzonase (Millipore) in the reaction buffer (10 mM Tris-HCl, 50 mM NaCl, 10 mM MgCl 2 , pH 8.0). These reactions were incubated at 37 o C for 4hrs for a complete breakdown of genomic DNA to individual nucleosides. The small molecule pool was isolated by using 3 kDa cutoff filters (VWR) and analyzed by HPLC. To generate 5-gmC standard, the genomic template from hmC-3 strain was treated with commercially available T4-BGT from New England Bioloabs. The resulting template was digested as described above. HPLC conditions -column -Luna 5µm C18 100 Å 250 x 2mm; solvent A: water; solvent B: 5 mM potassium phosphate buffer, pH 6.7; solvent C -methanol; flow rate -0.3 ml/min; 0 min -100%B, 7 min -100%B, 12 min -25%A 60%A 15%B, 18 min -25%A 10%B 65%C, 21 min -100%A, 30 min -100%A. InstrumentAgilent 1260 HPLC.
LCMS conditions: LCMS was used for the analysis of genomic DNA and plasmids for g-hmC strains. LC conditions -column -Zorbax SB-C18 5µm 4.6 x 15 mm; solvent A: 5 mM ammonium acetate buffer, pH 6.7; solvent B -0.1% formic acid in acetonitrile; flow rate -0.3 ml/min; 0 min -100%A, 7 min -100%A, 12 min -70%A 30%B, 17 min -30%A 70%B, 19 min -100%A, 28 min -100%A.
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Construction of plasmids:
PrimeStar master mix from Takara was used for all PCR reactions. All vector manipulation was performed using Quick Fusion cloning protocol from Biotool LLC or by using the Gibson protocol. 1 For DNA sequences -see SI pages S7-S9, for the spacer sequences -see Table S2 and for oligonucleotide sequences -see Table S3 .
Construction of pAM38:
Figure S1: Map for construct pAM38.
The genes were codon optimized using IDT software. Three gblocks (DNA sequence-1, DNA sequence-2, DNA sequence-3) were designed to cover the entire construct containing T4 gp 56, t4 gp 42, T4 gp 1 and T4 cd, which were separated by a defined spacer and ribosomal binding site (rbs) sequences. Initially DNA sequence-1 and DNA sequence-2 were amplified by using primers AM283/AM278 and AM279/AM289 respectively. They were combined by SOEing PCR. 2 The final PCR product was re-amplified by using primers AM283/AM289 and gel purified. The backbone pBAD-Tet vector was amplified from pAM22 3 using primers AM93/AM94. The two PCR products were combined by using Quick Fusion cloning protocol (Biotool LLC) to get an intermediate construct. This construct was linearized by using primers AM290/AM94 and DNA sequence-3 was amplified by using primers AM291/AM284. The two PCR products were combined by using Quick Fusion cloning protocol to get pAM38.
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Construction of pAM37: Figure S2 : Map for construct pAM37.
A combined sequence containing DNA sequence-1, DNA sequence-2 and DNA sequence-3 were amplified from pAM38 using primers AM413/AM414 and were inserted in pCdf-BAD vector containing Cdf ori and Chloramphenicol resistance (backbone amplified from pAM23 DNA sequence-4 (containing T4 gp 56, T4 gp 1) was amplified using primers AM323/AM324 and was inserted in inserted in pCdf-BAD vector containing Cdf ori and Spectinomycin resistance (backbone amplified from pAM23 3 using primers AM152/AM153). Further a spacer-2 sequence was introduced between the two genes by sequentially amplifying the above construct using primers AM319/AM320 and AM317/AM318. The linear product was circularized using KLD mixture from NEB (Q5 site-directed mutagenesis kit) to get pAM39. DNA sequence-5 corresponding to denB gene was amplified using primers AM435/AM432. It was further extended to include spacer-4 sequence by sequential amplification using primer pairs AM437/AM431 and AM442/AM439. This PCR product was inserted in pAM39 (pAM39 was linearized using AM322/AM153) to get pAM52. DNA sequence -6 coding for T4 bgt was amplified using primers AM425/AM426. pAM38 was linearized using AM282/AM94. The two PCR products were combined using Quick fusion protocol to get pAM53.
Construction of pAM76:
Figure S6: Map for construct pAM76.
Kanamycin resistance gene was amplified using primers AM348/AM349 and pACYCDuet-1 using primers AM350/AM351 and the chloramphenicol resistance of the standard vector pACYC-Duet-1 was switched to Kanamycin. The resulting vector was linearized using primers AM504/AM514 and DNA sequence -6 coding for T4 bgt was sequentially amplified S7 using primers AM515/AM424 and AM475/AM505 and the resulting products were combined to get pAM68. The T7/lacO promoter of pAM68 was switched to T5/lacO using primers AM627/AM628 and AM629/AM630. The linear product was circularized using KLD mixture from NEB (Q5 site-directed mutagenesis kit) to get pAM76.
Construction of pAM92:
Figure S7: Map for construct pAM92.
E. coli gene pgm was amplified from E. coli DH10B genome using primers AM489/AM490. This was further amplified using AM557/AM523 and inserted in pAM76 (pAM76 linearized using AM424/AM504) to get pAM77. E. coli gene galU was amplified from E. coli DH10B genome using primers AM528/AM529. galU was sequentially extended using primers AM533/AM529, AM534/AM529, AM535/AM529, AM536/AM711 to include spacer-4. The final product was inserted in pAM77 (pAM77 linearized using AM504/AM532) to get pAM84. Finally, to include a spacer sequence (spacer-5) between pgm and bgt, pAM84 was amplified using primers AM735/AM736 and the linear product was circularized using KLD mixture from NEB (Q5 site-directed mutagenesis kit) to get pAM92. ATGAAAATTGCCATCATCAATATGGGAAACAACGTGATTAATTTTAAAACAGTTCCTTCCTCGGAGACCA  TCTACCTGTTTAAGGTAATCTCTGAGATGGGCTTGAACGTCGACATCATTAGTTTGAAAAATGGCGTGTA  CACTAAGAGCTTTGACGAGGTTGATGTGAACGACTACGACCGCCTGATCGTAGTTAATTCTTCCATTAAT  TTTTTTGGGGGGAAACCAAATTTAGCAATTTTATCCGCGCAAAAATTCATGGCGAAGTATAAATCCAAGA  TCTATTATCTGTTTACCGACATCCGTCTGCCGTTCTCCCAGTCCTGGCCCAATGTCAAAAACCGCCCGTGG  GCTTACTTGTACACTGAAGAGGAATTGTTAATTAAGTCCCCAATCAAAGTAATCTCTCAAGGCATTAATC  TTGACATTGCTAAGGCAGCTCACAAAAAAGTTGATAATGTCATCGAGTTTGAATACTTTCCTATCGAACA  ATATAAAATCCATATGAATGACTTCCAACTTTCTAAGCCAACGAAAAAGACTCTTGACGTTATTTATGGC  GGAAGCTTCCGCTCAGGTCAGCGCGAAAGTAAAATGGTAGAATTCTTATTCGACACTGGATTGAATATT  GAATTTTTTGGCAACGCACGTGAGAAACAGTTCAAGAACCCTAAATATCCATGGACAAAGGCGCCTGTA  TTTACGGGGAAAATTCCCATGAATATGGTCTCTGAGAAAAACAGCCAAGCAATTGCAGCATTAATCATT  GGAGATAAAAACTATAACGACAACTTTATCACCCTTCGTGTTTGGGAGACCATGGCAAGTGATGCCGTC  ATGCTTATTGACGAAGAGTTCGACACGAAACATCGCATTATTAACGACGCCCGTTTTTACGTCAACAACC  GCGCCGAGTTAATTGATCGTGTTAATGAATTAAAGCACAGTGATGTCTTGCGTAAAGAGATGTTAAGCA  TCCAGCACGACATTCTTAATAAGACCCGCGCCAAAAAGGCAGAATGGCAAGACGCGTTTAAGAAAGCCA  TCGATCTGTGAGGTACCATATGGGAATTCGAAGCTTGGCTG   Table S3 : Oligonucleotides used in this study: 
